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Abstract: Diseases caused by chronic inflammation (e.g., arthritis, multiple sclerosis and 
diabetic ulcers) are multicausal, thus making treatment difficult and inefficient. Due to the 
age-associated nature of most of these disorders and the demographic transition towards an 
overall older population, efficient therapeutic intervention strategies will need to be 
developed in the near future. Over the past decades, elimination of activated macrophages 
using CD64-targeting immunotoxins has proven to be a promising way of resolving 
inflammation in animal models. More recent data have shown that the M1-polarized 
population of activated macrophages in particular is critically involved in the chronic 
phase. We recapitulate the latest progress in the development of IT. These have advanced 
from full-length antibodies, chemically coupled to bacterial toxins, into single chain 
variants of antibodies, genetically fused with fully human enzymes. These improvements 
have increased the range of possible target diseases, which now include chronic 
inflammatory diseases. At present there are no therapeutic strategies focusing on 
macrophages to treat chronic disorders. In this review, we focus on the role of different 
polarized macrophages and the potential of CD64-based IT to intervene in the process of 
chronic inflammation.  
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1. Introduction 
Immunotoxins (IT) are chimeric proteins consisting of a binding domain, which is commonly an 
antibody or a derivative thereof, and a toxic domain, which is an enzyme usually derived from bacteria 
or plants (Figure 1). Abbreviations: Ag, antigen; Ab, antibody; Fab, fragment antigen binding; scFv: 
single chain fragment variable. 
Figure 1. Basic architecture of Immunotoxins (IT). 
 
Classically, IT are comprised of a binding domain and a toxic domain, which optionally can be 
separated by an adapter peptide. The binding domain can be either a ligand (e.g., growth factor) or an 
antibody or a derivative thereof (e.g., scFv, Fab). The optional adapter peptide is used to improve 
translocation efficiency from the endosome into the cytosol. Naturally occurring adapter sequences can 
be derived from Pseudomonas Exotoxin A (ETA), which is composed of a binding domain (B), a 
translocation domain (A), and a toxic domain (T). Also, synthetic adapters containing an endosomal 
cleavable peptide (ECP), a membrane transfer peptide (MTP), and a cytosolic cleavable peptide (CCP) can 
be engineered. For cytotoxicity, bacteria-derived toxins (e.g., ETA, Diphtheria Toxin (DT)), plant-derived 
toxins (e.g., Ricin), or human enzymes (e.g., Granzyme B (Gb), Angiogenin (Ang)) can be used.  
After binding of the antibody to a target cell antigen, the IT is internalized followed by endosomal 
processing and final release of the toxin into the cytosol, where it induces cell death. In addition to 
antibodies as targeting units, several ligands including interleukins or growth factors have been  
used [1–7]. The internalization is almost exclusively dependent on the binding moiety and can vary 
strongly. In contrast, translocation to the cytosol can depend on several factors including the nature of 
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the toxic domain, the design of the fusion protein (e.g., translocation-supporting peptide sequences 
between the binding and the toxic domain), and the presence of a C-terminal endoplasmic reticulum 
(ER)-retention signal [8–10]. For plant toxins, for example, the intracellular transport was shown to be 
regulated by sorting receptors cycling between the ER and the Golgi [8]. The cytotoxicity of both plant 
and bacterial toxins was also shown to be optimal when the toxic domain only translocates to the 
cytosol [11]. Separation of both domains is usually accomplished by proteases, such as furin, which 
are predominantly localized in the transreticular Golgi [12]. An alternative way of translocation is 
presented by the bacterial diphtheria toxin (DT). Upon internalization and pH-mediated unfolding of 
the protein, DT forms a hairpin, which inserts into the membrane of early endosomes and translocates 
to the cytosol [13,14]. All of these modalities need to be considered for optimal design of IT.  
In the beginning of IT development, antibodies were conjugated to the protein toxin via chemical 
linking, which however has many disadvantages like separate production and purification of targeting 
and toxic unit, low yields after conjugation, and a non-directed coupling leading to a heterogeneous 
protein preparation [15]. To overcome these and to allow the commercial development of IT, 
recombinant IT were generated by genetically fusing the ligand and the toxin resulting in a single 
chain DNA construct. To date, most IT can be simply expressed by fermentation of transformed 
Escherichia coli or by transiently transfected HEK293T cells and purified by standard chromatographic 
methods. One of the criteria for the toxic domain of the IT of choice is the ability to induce apoptosis. 
Induction of apoptosis as opposed to necrosis or pyroptosis is the preferred result of the IT, as it 
reflects a way of strongly regulated cell death without severely affecting the local environment [16,17]. 
The most prominent toxins which have been used so far are plant-derived ricin, especially the A chain 
thereof, bacterial Pseudomonas Exotoxin A (ETA), and DT [18]. Ricin belongs to the class II 
ribosome-inactivating proteins, which contain both binding and toxic domains and are therefore called 
holotoxins. Further members of this group are abrin, mistletoe lectin, and modeccin [19]. Plant toxins 
containing only a catalytic domain (e.g., saporin, bouganin, and gelonin) belong to the class I 
ribosome-inactivating proteins and are called hemitoxins [20]. All of these plant toxins have in 
common that they prevent the association of elongation factor (EF) 1 and 2 with the 60S ribosomal 
subunit [21,22].  
In contrast, bacterial toxins, including ETA and DT, inhibit protein synthesis by enzymatically 
catalyzing the adenosine diphosphate ribosylation of EF2 in the cytosol [23,24]. Both bacterial toxins 
are multidomain proteins comprising a cell-binding and a toxic domain separated by a translocation 
domain. For use in IT, truncated versions of ETA and DT are generated by deletion of the cell binding 
domain [25–29]. This reduces the size of ETA and DT, respectively, making them even more suitable 
as fusion proteins and it increases their specificity preventing unwanted binding to healthy cells. The 
most prominent shortened version of ETA is PE38 (here referred to as ETA’) [27]. Historically, due to 
their relatively strong side effects, IT have been implicated for use in life threatening disease only and 
were therefore restricted to indications such as cancer. Recently, Madhumthi and Verma reviewed 
existing therapeutic targets for immunotherapy emphasizing that cancer, including solid tumors, 
lymphoma, and leukemia, represents the dominating indication for classical IT [30]. Besides their toxic 
side effects, immunogenicity of chimeric IT composed of a murine or human antibody and a bacterial 
or plant toxin had to be considered as an obstacle for treatment [31]. Generation of neutralizing 
antibodies by the immune system would reduce the number of possible treatment cycles. Different 
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attempts have been done to reduce immunogenicity. For example, potential T- and B-cell epitopes on ETA 
have been identified and mutated expecting a less immunogenic version of the bacterial toxin [32–34]. An 
alternative strategy is to modify the IT using polyethylene glycol, which has been proved to be 
efficient in preventing immunogenicity of interferon and L-asparaginase [35–37]. However, these 
strategies up to now failed to significantly reduce immunogenicity. Vascular leak syndrome triggered 
by binding of toxins to endothelial cells represents another disadvantage of chimeric IT. As  
counter-measures, receptor mutation, inhibitors preventing the binding to endothelial cells and 
administration of anti-inflammatory agents have been taken [38]. Low or non-killing concentrations of 
such IT have also been reported to induce an enhanced inflammatory response via activation of innate 
immune sensors [39–41]. This fact is especially relevant in the context of treating inflammatory 
diseases as it would oppose the desired effect of resolving inflammation. A far more promising 
approach is presented by the generation of fully human cytolytic fusion proteins (hCFP). Fully human 
antibodies fused to human proteins, which are capable of directly or indirectly inducing apoptosis, are 
now gaining attention due to their safety. A dozen successfully applied hCFP already exist. Human 
RNases like RNase 1, 2, 3 and 5 (angiogenin), which degrade RNA and induce apoptosis by inhibition 
of protein synthesis, have been used to replace the non-human toxins [42]. Huhn et al. were able to 
show specific cytotoxicity of the human angiogenin to CD30 overexpressing Hodgkin lymphoma-derived 
cell lines delivered by a CD30 ligand (CD30L) [43]. Another hCFP CD30L-based IT was generated by 
Tur et al. who showed specific cytotoxicity of the human death associated protein kinase 2 towards 
several Hodgkin lymphoma cells in vitro [44,45]. Proapoptotic proteins such as Bik, Bak, Bax, DNA 
fragmentation factor 40, FAS-ligand, and TNF-related apoptosis-inducing ligand proofed effective in 
melanoma, renal cancer, cutaneous T cell lymphoma, and AML [46]. A novel IT composed of a scFv 
against CTLA4 and perforin was shown to kill CTLA-positive cell lines in vitro [47]. Although most 
of the IT were tested for toxicity on cancer cells, hCFP presenting a safe and non-immunogenic profile 
would allow for their application in diseases other than cancer. One interesting and, at the same time, 
challenging class of diseases which often lack effective and specific therapy are chronic inflammatory 
disorders. As macrophages are strongly involved in inflammation, they have been suggested to 
represent a suitable target for therapy. 
2. The Role of Macrophages in Immunity 
Macrophages belong to the mononuclear phagocytic system and are present in virtually all tissues. 
They originate from hematopoetic stem cells in bone marrow, which develop into blood circulating 
monocytes followed by a regulated migration into different tissues, either in steady state or upon 
inflammation. There, they finally differentiate into tissue-specific macrophages [48]. The 
nomenclature of terminally differentiated macrophages comprises among others osteoclasts in  
bone-marrow, microglial cells in the central nervous system, alveolar macrophages in lungs, Kupffer 
cells in the liver, and various forms of spleen macrophages [49]. These strongly phagocytic cells have 
long been considered to play a key role in the immune system. For the very first description of 
phagocytosis and its importance for immunity, Metchnikoff was awarded with the Nobel prize in 1908 
[49,50]. This discovery has inspired immunologists to explore the function of macrophages as immune 
effector cells and to broaden the understanding of how these cells participate in direct host defense. 
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Over time, their original function of pathogenic and homeostatic clearance, which includes the 
essential recycling of iron by engulfment of erythrocytes, and the removal of cell debris derived from 
tissue remodeling, apoptosis and necrosis, was extended to more complex physiological processes 
[49,51–53]. It is now known that they are potent inducers and regulators of immune responses and take 
a central role in orchestration of many metabolic functions in health and disease. Inflammation is one 
of the conditions, where macrophages play a critical role. The release of cytokines from apoptotic 
neutrophils, which are the first cells to infiltrate the site of inflammation [54], subsequently leads to the 
recruitment of macrophages which then guide the course of inflammation until resolution is achieved. 
In wound healing for instance, macrophages participate in all three major phases comprising 
inflammation, new tissue formation and tissue remodeling through communication with keratinocytes 
[55–57], fibroblasts and myofibroblasts [58–62], and endothelial cells [63–66]. For this very reason, 
macrophages play a key role in ensuring a physiologically normal inflammation. In consequence, 
pathology and proper resolution of inflammation are very close to each other in macrophage-
coordinated events. 
3. Classification of Polarized Macrophages and Their Contribution to Inflammation 
Inflammation is a complex and dynamic physiological process, which requires a well-balanced and 
controlled interaction of diverse cells. One of the cell types critically involved in initiation but also 
resolution of inflammation is macrophages. Across the different phases of an inflammatory response to 
e.g., infections or skin damage, their functions cover the production of pro-inflammatory cytokines and 
cytotoxic compounds, secretion of various growth factors to promote the function of other cells 
contributing to the resolution of inflammation, fighting invading microbes, and scavenging cell debris. 
In fact, these factors are neither produced simultaneously nor by the same kind of macrophages. 
Several recent reports have made clear that “the” macrophage does not exist, but that the term 
macrophage is rather used in a broader context for the description of a population of very versatile 
cells that share some common denominators. Due to their ability to adopt to a changing cytokine 
milieu and, vice versa, to influence the milieu by production of an array of soluble mediators, 
macrophages are nowadays considered to be very plastic and flexible cells [67]. Acquiring diverse 
functional phenotypes in response to environmental cues is reflected in the classification of polarized 
rather than activated macrophages. Mirroring the Th1/Th2 dichotomy, polarized macrophages were 
sub-divided into M1 and M2. M1 polarization, also referred to as classical activation, results from 
stimulation with Interferon-γ (IFN-γ), alone or in concert with bacterial lipopolysaccharide (LPS) [68]. 
The source of IFN-γ can be both innate and adaptive immune cells. Upon stress or first encounter to 
pathogens, natural killer (NK) cells, as part of the innate immunity, produce IFN-γ, thus polarizing 
macrophages to M1. In addition, an increased capacity of antigen presenting [69,70], these M1 cells 
are characterized by an enhanced microbicidal and tumoricidal activity mediated by the production of 
increased levels of superoxide anions, and oxygen and nitrogen radicals, which in summary confers 
direct host resistance to infections [71–73]. However, the capability of NK cells to provide sustainable 
amounts of IFN-γ is limited. Since M1 macrophages induce a Th1 response by secretion of high levels 
of pro-inflammatory cytokines, such as interleukin (IL)-12, IL-23, and tumor necrosis factor (TNF)-α, 
the polarization of macrophages to M1 can be amplified by a continued supply with IFN-γ by T cells. 
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In contrast to T cells, which act in an antigen-specific manner, M1 polarized macrophages kill 
unspecifically, merely restricted by the distance to the target cell. While M1 macrophages represent the 
one extreme of polarization, the second extreme is summarized under the term alternatively activated 
macrophages or M2 macrophages [52]. During the past decade, this term has been expanded to a more 
heterogeneous cell population [74,75]. The nomenclature of alternatively activated macrophages is 
somewhat confusing and changes over time. Terms used are: M2, alternatively activated macrophages, 
type II activated macrophages, deactivated macrophages, M2a, M2b and M2c and a few more. In effort 
to find a more informative and clear classification of polarized macrophages Mosser and Edwards [49] 
suggested the following three sub-populations based on their functions: host defense, wound healing 
and immune regulation. This classification is in accordance with that proposed by Mantovani et al. [69], 
where M1 would refer to host defense, M2a to wound healing and M2b together with M2c to immune 
regulation. For discrimination of different macrophage phenotypes, Mantovani et al. not only 
considered the function, but also the respective stimuli generating the sub-populations. Thereby, M2a 
is produced by IL-4 or IL-13 both of which activate STAT6 via binding to the IL-4 α-subunit, which is 
shared in both receptors [76–80]. M2b results from a combined exposure to immune complexes with 
Toll-like receptor (TLR)- or IL-1 receptor (IL1R)-ligands, whereas M2c is induced by IL-10 [69]. 
Supplementary to Mossers and Edwards’s classification, Mantovani et al. discriminate between M2b 
macrophages, which in addition to immunoregulatory functions also induce Th2 driven inflammation, 
and M2c macrophages, which are thought to be predominantly responsible for negative/deactivating 
immunoregulation. More recently, additional sub-populations of macrophages were discovered (Figure 2). 
Diverse ways of polarizing macrophages are induced by distinct signals from the microenvironment. 
Unpolarized macrophages/monocytes (M0) acquire a M1 phenotype upon stimulation with IFN-γ and 
LPS. M2a macrophages, especially responsible for wound healing, result from exposure to IL-4 or  
IL-13. Other members of the alternatively activated macrophages include M2b (after exposure to  
IC + TLR-ligands or IL-1R ligands) and M2c (polarized by IL-10). M2d represents a more recently 
discovered macrophage subset, which results from re-polarization from M1 by adenosine signaling. 
Whether an initial stimulus polarizing M0 to M2d does exist is yet unknown. The apparently related 
subsets Mox and Mha can be generated in vitro by stimulation with Ox-PL-PPC and HH-complexes or 
oxRBS, respectively. M2 macrophages are a hydride-type subset with combined features of M1 and 
M2 macrophages. These cells were shown to be CSF/CXCL4-dependent.  
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Figure 2. Different polarized MΦ subsets. Abbreviations: IC, immune complex; TLR, 
Toll-like receptor; IL-1R, IL-1 receptor; Ox-PL-PPC, ox-PL 1-palmitoyl-2arachidonoyl-
sn-glycero-3-phosphorylcholine; HH-complexes, hapto-hemoglobin; oxRBC, oxidized red 
blood cells; CSF, colony stimulating factor; CXCL4, chemokine (C-X-C motif) ligand 4. 
 
In the context of atherosclerosis, a population of macrophages expressing a unique set of genes 
including Heme oxygenase-1 (HO-1), sufiredoxin-1, and thioredoxin-reductase in a nuclear factor, 
erythroid-derived 2, like 2(Nrf2) dependent manner was found within the aortas of 30 week western 
diet-fed Ldlr−/− mice by immunohistochemistry and flow cytometry. In vitro, this phenotype could be 
induced by ox-PL 1-palmitoyl- 2arachidonoyl-sn-glycero-3-phosphorylcholine resulting in the 
designation as Mox macrophages [81]. Furthermore, Mox macrophages seem to be closely related to 
the lately proposed hemorrhage-associated macrophages (Mha) [82,83]. Human monocytes can be 
differentiated to Mha macrophages in vitro using hapto-hemoglobin complexes or oxidized red blood 
cells leading to the up-regulation of CD163, HO-1 and IL-10 in an Nrf2-dependent manner. Moreover, 
a CSF/CXCL4-dependent macrophage subset, discovered in 2010 by Gleissner et al. [84], was termed 
M4. These macrophages were shown to be characterized by a mixed, but unique profile of transcripts 
including higher levels of CD86 and TNF-α (both M1-like), CD206, CCL18 and CCL20 (all M2-like) 
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and lower levels of pentraxin 3 (PTX3), CD36 and IL-10 (M2-like). Although these cells have a weak 
phagocytic activity, the function of M4 macrophages remains poorly understood. Finally, the 
laboratory of Samuel Joseph Leibovich has characterized one further M2 subtype, termed M2d, which 
unlike previously described M2-like macrophages, are the result of a switching event from M1 
macrophages as response to adenosine A2A receptor signaling induced by TLR agonists [85]. M2d 
macrophages were demonstrated to markedly decrease the expression of pro-inflammatory cytokines 
including IL-12 and TNF-α, while concurrently producing high levels of IL-10 and vascular 
endothelial growth factor (VEGF). Interestingly, the classical markers of wound healing or M2a 
macrophages were not up-regulated pointing to an M2c-resembling phenotype of M2d macrophages. 
The phenotypes of different polarized macrophages are summarized in Figure 3. 
Figure 3. Phenotypes of different polarized MΦ. 
 
Polarized macrophages show characteristic expression profiles of surface receptors and soluble 
mediators. M1 macrophages are characterized by an elevated expression of the co-stimulatory 
receptors for T cell activation CD80 and CD86 and both MHC molecules underlining their role as 
potent antigen presenting cells. On the soluble level, M1 macrophages up-regulate the expression and 
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secretion of pro-inflammatory cytokines, such as IL-12, IL-6, and TNF-α. In contrast, M2 (a-d) 
macrophages preferentially produce anti-inflammatory cytokines (e.g., IL-10). Another hallmark of 
M2 macrophages (especially M2a and M2c) is the up-regulation of the mannose receptor (CD206). 
Recently identified macrophage subsets (M4, Mox and Mha) have until now been poorly 
characterized. Abbreviations: MHCI/II, major histocompatibility complex I/II; SLAM, signaling 
lymphocytic activation molecule; RNI, reactive nitrogen intermediates; ROI, reactive oxygen 
intermediates; iNOS, inducible nitric oxide synthase; RELM-α, resistin-like molecule α; YM1, heparin 
binding lectin; Arg, arginase; TGF-β, tumor growth factor β; PTX3, pentraxin 3; VEGF, vascular 
endothelial growth factor; CCL18/20, chemokine (C-C motif) ligand 18/20; HO-1, heme oxygenase-1 
(HO-1); SD-1, sufiredoxin-1; TR-reductase, thioredoxin-reductase. 
Together, this huge diversity in alternatively activated macrophages illustrates how different 
physiological processes might be accurately regulated by distinct macrophage subsets depending on 
the environmental conditions given. As already exemplified for M2d, all polarization subsets are also 
believed to be plastic and to undergo phenotypical and functional switches upon signals from the 
milieu, thus making the versatility of the macrophage system even vaster than that which emerges from 
the initial polarizing stimulus. However, imbalance and/or dysregulation of macrophage-controlled 
processes are strongly associated with a pathological outcome including several autoimmune diseases, 
impaired wound healing, metabolic disorders, and cancer [86–93]. Mediated by an autocrine secretion, 
certain macrophage subsets sustainably maintain the cytokine milieu leading to the persistence of these 
cells for an inappropriate period of time. In addition, T cells become activated and further promote the 
inflammatory status. Both cell types, T cells and macrophages, are initiators of different inflammatory 
diseases and can be used as targets in diagnosis and therapy. Based on the recently acquired knowledge 
on the involvement of distinct polarized macrophages in certain diseases and the anticipated rapid 
increase of novel findings in this field, polarized macrophages are more and more becoming an object 
of interest. Selective depletion of distinct macrophage populations, without adversely affecting others 
would allow for selective therapy with fewer side effects. However, polarization of macrophages 
represents a fairly new field of research and little is presently known on the origin, function, and 
plasticity of different polarized macrophages. So far, no effective therapies selectively targeting one 
population of macrophages do exist. 
4. Improved CD64-Targeting Immunotoxins for Therapy of Chronic Inflammatory Diseases 
Due to the demographic transition towards an overall older population, which is expected to 
continue growing in the next years, age-associated disorders are becoming more and more relevant to 
the welfare of our population. Following this tendency, the ratio of care-dependent people to care 
assistants is anticipated to increase significantly. As a result, the economic burden for the public health 
system will be devastating. Among cardiovascular diseases and cancer, disorders caused by chronic 
inflammation also belong to the class of age-associated widespread diseases. However, since no 
specific targets exist for most of the inflammatory diseases, current medical therapy relies on primarily 
facilitative and symptomatic rather curative treatments. Treatment of rheumatoid arthritis, for example, 
consists of blocking the effect of TNF-α, a pro-inflammatory cytokine secreted by activated 
inflammatory macrophage, using monoclonal antibodies, such as infliximab, etanercept or  
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adalimumab [94]. Mesalamine or 5-aminosalicyl acid is another anti-inflammatory drug which is 
routinely used for treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s 
disease [95,96]. Targeting and depleting T cells via IL-2 receptor [97], regulated on activation normal 
T cells expressed and secreted (RANTES) [98], CCR5 [99], CD5, VLA-4, CD69, CD44, CD40 ligand 
and Ox-40 have been implicated in therapy of inflammatory diseases including psoriasis and 
rheumatoid arthritis, renal diseases, multiple sclerosis, diabetes, graft versus host disease, systemic 
lupus erythematosus, autoimmune dermatoses and oophoritis, to name just a few.  
However, clinical management consisting of blocking pro-inflammatory cytokines target the 
amplification loop of inflammation by depleting secondary inflammatory signals (e.g., TNF-α). 
Beyond that, depletion of specific subsets of antigen specific T cells is associated with the undesirable 
reduction of the immune systems diversity. An intervention in processes that do not amplify, but rather 
cause the imbalance of pro- and anti-inflammatory cytokines would potentially result in a more 
rational approach to suppress chronic inflammation. One suitable target for this approach are 
macrophages which substantially contribute to chronicity by production of pro-inflammatory soluble 
mediators. To allow specific targeting of these cells, a surface molecule had to be selected to act as an 
entrance mediator. Screening of surface expression revealed FcγRI, also referred to as CD64, to be  
up-regulated in macrophages. Compared to the other three Fcγ receptors (i.e., FcγRII (CD32), FcγRIII 
(CD16) and neonatal FcγR), CD64 displays several exclusive properties: (1) high affinity; (2) ability to 
bind and internalize monomeric IgG [100]; and (3) constitutive expression only on macrophages, 
monocytes and their progenitors [101–103]. These properties make CD64 a suitable target molecule 
for a selective therapy directed against macrophages. First evidence for the success of this strategy was 
given by Thepen et al. in 2000, when elimination of CD64-positive macrophages using the IT H22-RicinA 
was demonstrated to resolve chronic skin inflammation in transgenic mice within 24 h [104]. In 
addition, Thepen et al. also showed by histological examination that other inflammatory cells 
disappeared from the site of inflammation and clinical parameters like vascular leakage and increased 
temperature were restored. Six years later, the same laboratory showed the inhibition of progression of 
arthritis in a rat model [105] and efficient killing of activated macrophages from synovial fluid 
obtained from human rheumatoid arthritis patients using the same IT [105]. The therapeutic approach 
of targeting macrophages by H22-based IT was then transferred to an ischemia-reperfusion rat model, 
where Fet et al. showed that treatment with H22(scFv)-ETA’ was effective to preserve renal function 
and morphology and ameliorated ischemia-induced kidney injury [106]. Although elimination of 
activated macrophages proofed effective in the treatment of inflammatory diseases, this strategy needs 
to be considered with caution when transferred to other macrophage-associated diseases. For example, 
during pulmonary tuberculosis in mice macrophages were shown to have a dual function. While  
non-specific depletion of all macrophages using liposomes improved clinical outcome, specific 
elimination of activated macrophages only led to impaired resistance to infection, reflected by 
enhanced mycobacterial outgrowth [107]. This study gives a further example for the existence of 
distinct macrophage populations, each fulfilling another function.  
The successful application of H22-RicinA and H22(scFv)-ETA’ in different therapeutic approaches, 
not only the inflammatory diseases described above, but also cancer, has moved forward the 
development of IT containing potentially immunogenic plant- or bacteria-derived toxins to a new 
generation of hCFP. The rational approach of selecting human enzymes suitable to act as a toxin was 
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based on their ability to induce apoptosis in target cells. Stahnke et al. found human Granzyme B to 
confer specific killing to primary CD64-positive cells from an acute myeloid leukemia (AML) patient 
ex vivo and to AML-related cell line U937 in vitro after delivery by H22(scFv). The cytotoxicity was 
shown to be mediated by activation of caspase-3 leading to the induction of apoptosis and the half-maximal 
inhibitory concentration (IC50) was in the range of 1.7–17 nM, underlining the efficacy of the hCFP [108]. 
To further exploit possible strategies to improve the performance of hCFP, two critical parameters 
were investigated: (1) internalization and (2) translocation from endosomes into the cytosol. Although 
cross-linking is not required for internalization of CD64, it is known to be an enhancing factor [102,109]. 
Therefore, a bivalent construct was engineered resulting in H22(scFv)2-IT. Indeed, this IT proofed 
more effective in vitro and in a SLS induced chronic cutaneous inflammation model in transgenic mice 
in vivo [110]. The second and more sophisticated adaptation was the insertion of short  
translocation-supporting peptide sequences between the C-terminus of the scFv and the N-terminus of 
a human enzyme. Translocation is one of the bottlenecks when applying IT via the receptor-mediated 
endocytosis pathway and is therefore a crucial part of IT development. This fact is especially true for 
human enzymes as they originally do not contain a translocation domain, which is in contrast to bacterial 
toxins (e.g., ETA). In fact, Hetzel et al. demonstrated improved efficacy of H22(scFv)-Angiogenin by 
insertion of small cleavable adapter sequences containing a synthetic translocation domain flanked by 
proteolytically cleavable endosomal and cytosolic consensus sites. Consequently, enhanced 
translocation resulted in 20-fold cytotoxicity and a superior serum stability of the hCFP [111]. 
Taken together, targeting macrophages by IT has been repeatedly shown to be a suitable tactic for 
treatment of chronic inflammatory diseases and also cancer. The presence of different types of 
macrophages at different phases of chronic inflammation would make the targeting of the distinct  
sub-populations an attractive therapeutic approach. However, treating chronic disorders requires 
repetitive administration of the therapeutic, which in case of not fully human IT would lead to 
immunogenicity, thus making the treatment ineffective. In addition, approval of therapeutics 
containing bacteria- or plant-derived components would also present a challenging, if not an 
impossible task. To overcome these drawbacks, hCFP were developed over time and proofed effective 
for different indications in vitro and in vivo. 
5. Conclusions  
IT have emerged as a powerful tool for targeted therapy of many diseases. Due to unspecific 
cytotoxicity, immunogenicity and other undesired side effects, the use of IT in the clinic has been 
predominantly limited to treatment of life-threatening diseases, such as cancer, only. However, new 
generation IT, which are now composed of fully human proteins, overcome these disadvantages 
resulting in an increased application range of these hCFP. New indications also cover the class of 
chronic inflammatory disorders. Thereby, elimination of macrophages rather than antigen-specific T cells 
as major producers of inflammatory cytokines was demonstrated to be a more indulgent principle of 
how an impaired inflammation can be brought under control. Currently, polarization of macrophages, 
their phenotypes and functions, and most importantly, their involvement in diseases are being 
extensively studied. Due to their plasticity, macrophages undergo phenotypical and functional switches 
during the course of the disease. Identification of distinct macrophage subsets, which are critically 
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involved in the pathology of the disease, and development of suitable targeting approaches for 
elimination of these macrophages would allow for an effective and side effect poor treatment of many 
inflammatory and autoimmune disorders. Moreover, the assignment of one specific macrophage  
sub-population is not limited only to inflammation. For instance, M2c macrophage are thought to be 
the so-called tumor-associated macrophages supporting the tumor cells in escaping from the immune 
system and promoting the vascularization of the tumor body. We anticipate that in near future, it will 
be possible to identify strategies to target individual subsets of macrophages without adversely 
affecting the pathology-unrelated populations of macrophages.  
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